FAQ

  • Who is AxoGen?
  • AxoGen, Inc. is a regenerative medicine company focused on the development and commercialization of technologies for peripheral nerve reconstruction and regeneration. The Company has created and licensed a unique combination of patented technologies and offers a full portfolio of nerve repair and protection solutions for patients with peripheral nerve injuries.

  • What products does AxoGen offer?
  • AxoGen's products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available allograft nerve for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments.

  • How does AxoGen plan to maintain a competitive advantage in the peripheral nerve graft market?
  • AxoGen provides a patent protected product suite that addresses the surgical peripheral nerve continuum. Avance® Nerve Graft is a product used in nerve reconstruction where the gap between the nerve ends is typically greater than 5mm. AxoGen developed Avance® Nerve Graft by following the guiding principle that the human body created the optimal nerve structure. Processed from recovered human peripheral nerve tissue, Avance® Nerve Graft provides the natural nerve structure of an autograft nerve but with the ease and availability of an off-the-shelf product.

    AxoGuard® Nerve Protector minimizes the potential for soft tissue attachments and nerve entrapment by physically isolating the nerve during the healing process.

    AxoGuard® Nerve Connector is for gaps between the nerve ends up to 5mm and provides a coaptation aid for the reconstruction.

    Both AxoGuard® Nerve Protector and AxoGuard® Nerve Connector provide the unique features of pliability, suturability, and translucence for visualization of the underlying nerve while allowing the patient's own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the nerve epineurium.

    Through R&D, licensing or acquisition, AxoGen will also continue to expand its product offering with products that Bring the Science of Nerve Repair to Life.

  • What is AxoGen, Inc.'s stock symbol?
  • Our stock is traded on the NASDAQ under the symbol AXGN.

  • Can I buy stock directly from AxoGen, Inc.?
  • No, you will need to contact a licensed stock broker or use an online trading account.

  • How can I buy stock in AxoGen, Inc.?
  • Through a licensed stock broker or by using an online trading account.

  • How do I change the address on my shareholder account?
  • Through your brokerage account or by contacting our transfer agent.

  • Where is AxoGen, Inc. located?
  • 13631 Progress Blvd.
    Suite 400
    Alachua, FL 32615

  • When is AxoGen, Inc.'s fiscal year end?
  • December 31st

  • Who is AxoGen, Inc.'s transfer agent?
  • Wells Fargo Shareowner Services
    P.O. Box 64874
    St. Paul, MN 55164
    T: 800-401-1957
    www.wellsfargo.com/com/shareowner_services

  • Who are AxoGen, Inc.'s independent auditors?
  • Lurie Besikof Lapidus & Company, LLP
    2501 Wayzata Boulevard
    Minneapolis, MN 55405
    T: 612-377-4404

  • Who is AxoGen, Inc.'s outside legal counsel?
  • DLA Piper LLP (US)
    One Liberty Place
    1650 Market Street, Suite 4900
    Philadelphia, PA 19103-7300

  • Does AxoGen pay a dividend and when will it be paid?
  • AxoGen does not pay a dividend at this time. Future dividends will be determined by the Board of Directors.

  • How do I get a copy of the company's financial statements, such as an Annual Report, SEC filings?
  • Annual Reports, SEC filings, and financial statements are available for viewing on this website and can also be downloaded or printed. To sign up to be notified when the Annual Report or latest SEC filing is available, please visit the Email Alerts section of the Investors page.

  • How do I contact AxoGen Investor Relations?
  • Investor Relations
    AxoGen, Inc.
    13631 Progress Blvd.
    Suite 400
    Alachua, FL 32615
    Email: InvestorRelations@AxoGenInc.com

    Customer Care:
    Toll Free (US) 888-AXOGEN1 (888.296.4361)
    Direct Dial: 386.462.6880
    Fax: 386.462.6801 (Fax)